Nathan Reticker-Flynn is a Biomedical Engineer and tumor immunologist working at the interfaces of cancer metastasis, tumor evolution, adaptive immunity, and immuno-oncology. He received his Ph.D. from the Massachusetts Institute of Technology while working with Dr. Sangeeta Bhatia as part of the Harvard-MIT Division of Health Sciences and Technology. His doctoral studies focused on developing technologies for interrogating interactions between tumors and extracellular matrix during metastatic progression. Dr. Reticker-Flynn performed his postdoctoral studies in the laboratory of Dr. Edgar Engleman at Stanford University School of Medicine. There, his work has focused on using systems approaches and mouse models to investigate tumor-immune interactions during metastasis and responses to immunotherapies. His discoveries include the revelation that effective immunotherapies require systemic activation of anti-tumor immunity and that lymph node metastases serve to reeducate adaptive immune responses in a manner that promotes distant metastasis. He currently focuses on using systems approaches and mouse models to elucidate the mechanisms of tumor-immune tolerance during metastatic progression and to develop novel immunotherapies to treat patients with metastatic disease.
Current role
Scientific Advisor And Co-founder at Transformative
Managing Partner & Senior Scientific Advisor at Brookline Capital Markets
Chair of the Scientific Advisory Board at Therini Bio, Inc.
Scientific Advisor at zPREDICTA
Co-Founder and Scientific Advisor at Amorphology, Inc
Access the worlds's biggest network of public org charts
Learn more